Halozyme Therapeutics Inc., is the development stage biopharmaceutical company which is exclusively devoted for developing and commercializing the recombinant human enzymes for the ophthalmology community vide their amazing product known as Enhanze SC. The company’s portfolio of products in development is entirely based on intellectual property incorporating the family of human enzymes that are known as hyaluronidases. The first recombinant human hyaluronidase – rHuPH20 is the enrichment agent known as Enhanze SC.

Enhanze SC is one of the leading products of Halozyme which is exclusively designed for use as the spreading agent to enhance the drug delivery of the local anesthesia during the cataract surgeries. The drug is also considered as the contrast agents and for subcutaneous fluid replacement also known as hypodermoclysis. The product is intending the established markets and is based on the proprietary technology platform offering momentous aggressive safety and effectiveness benefits evaluated with presently available substitutes.

Halozyme had received the official confirmation form the Foods and Drugs Administration of the United States on March 3rd in the year 2005 which stated that the drug Enhanze SC would be designated the New Entity. It was considered as the most vital product of Halozyme according to the company’s Managing Director cum Chairman cum   CEO. Halozyme has entered into the exclusive agreement with Baxter Healthcare Corporation for Baxter for marketing, distributing and selling its wonder product Enhanze SC for certain indications in the United States and Puerto Rico after approval of the therapeutic by the US FDA authorities.

Enhanze SC is designed to offer the synthetic substitutes of impure enzymes derived from the slaughter houses that carry risks of animal pathogen contamination as well as the immuno genicity that are presently used in the infertility and ophthalmology markets all over the world. The versatility of the first enzyme rHuPH20 has enabled Halozyme to simultaneously market the product as the medical device, drug enhancement agent as well as the therapeutic biologic.